What is the translation of " SOFOSBUVIR " in Slovenian?

• sofosbuvir
• sophosbuvir
• sofobuvirjem
• sofobusvirjem
• pri sofosbuvirja

Examples of using Sofosbuvir in English and their translations into Slovenian

Sofosbuvir(400 mg once daily)/.
Ofosbuvir 400 mg enkrat.

Use with ledipasvir and sofosbuvir.
Uporaba z ledipasvirjem in sofobusvirjem.

Median sofosbuvir EC50, nM(range).
Povprečna vrednost EC50 za sofosbuvir, nM(razpon).

See also under Use with ledipasvir and sofosbuvir below.
Glejte tudi poglavje Uporaba z ledipasvirjem in sofobusvirjem v nadaljevanju.

Monotherapy with Sofosbuvir is not recommended;
Monoterapija z zdravilom Sofosbuvir ni priporočljiva;

Each analogue contains in its composition a certain amount of ledipasvir and sofosbuvir.
Vsak analog vsebuje v svoji sestavi določeno količino Ledipasvir in Sofosbuvira.

Ciclosporin(600 mg single dose)/ sofosbuvir(400 mg single dose)f.
Ciklosporin(600 mg enkratni odmerek)/sofosbuvir(400 mg enkratni odmerek)f.

Sofosbuvir and GS-331007 AUCs are near dose-proportional over the dose range of 200 mg to 1,200 mg.
Vrednosti AUC za sofosbuvir in GS-331007 sta skoraj sorazmerni z odmerkom v razponu odmerka 200- 1.200 mg.

Previously treated adults who have failed on sofosbuvir+ ribavirin± PEG-IFN.
Predhodno zdravljeni odrasli, pri katerih je bilo zdravljenje s sofobuvirjem+ ribavirinom ± PEG-IFN neuspešno.

Sofosbuvir is a substrate of drug transporter P-gp and breast cancer resistance protein(BCRP) while GS-331007 is not.
Sophosbuvir je substrat P-gp in BCRP, medtem ko njegov neaktiven metabolit(GS-331007)- ni.

The clinical data to support the use of Daklinza and sofosbuvir in patients infected with HCV genotypes 4 and 6 are limited.
Klinični podatki, ki bi podpirali uporabo zdravila Daklinza in sofosbuvirja pri bolnikih, okuženih z genotipoma 4 in 6 HCV, so omejeni.

Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 400 mg.
Vrednosti AUC za Sofosbuvir in GS-331007 sta skoraj sorazmerni z odmerkom v razponu odmerka od 200 mg do 400 mg.

The highest documented doses of ledipasvir and sofosbuvir were 120 mg twice daily for 10 days and a single dose of 1,200 mg, respectively.
Najvišja dokumentirana odmerka ledipasvirja in sofosbuvirja sta bila 120 mg dvakrat na dan 10 dni oz. enkratni odmerek 1.200 mg.

Sofosbuvir and GS-331007 AUC0-24 and Cmax were similar in healthy adult subjects and patients with HCV infection.
Vrednosti AUC0-24 in Cmax za sofosbuvir in GS-331007 sta bili podobni pri zdravih odraslih osebah in bolnikih z okužbo s HCV.

The highest documented doses of Ledipasvir and Sofosbuvir are 120 mg twice per day for 10 days, and a single dose of 1200 mg, respectively.
Najvišja dokumentirana odmerka ledipasvirja in sofosbuvirja sta bila 120 mg dvakrat na dan 10 dni oz. enkratni odmerek 1.200 mg.

Sofosbuvir and GS-331007 are not substrates or inhibitors of UGT1A1 or CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 enzymes.
Sofosbuvir in GS-331007 nista substrata ali zaviralca encimov UGT1A1 ali CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 in CYP2D6.

Table 4: Adverse drug reactions identified with sofosbuvir in combination with ribavirin or peginterferon alfa and ribavirin.
Preglednica 4: Neželeni učinki zdravila, identificirani pri sofosbuvirju v kombinaciji z ribavirinom ali s peginterferonom alfa in ribavirinom.

The sofosbuvir resistance-associated substitution S282T emerged in only 1 non-SVR12 patient infected with genotype 3.
Substitucija S282T, povezana z odpornostjo proti sofosbuvirju, se je pojavila le pri 1 bolniku, okuženem z genotipom 3, pri katerem SVR12 ni bil dosežen.

In clinical studies of Daklinza in combination with sofosbuvir with or without ribavirin, 2% of patients had Grade 3 haemoglobin decreases;
V kliničnih študijah zdravila Daklinza v kombinaciji s sofosfubovirjem, z ribavirinom ali brez njega, so pri 2% bolnikov poročali o zmanjšanju vrednosti hemoglobina stopnje 3.

Sofosbuvir and GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of drugs that are substrates of these transporters.
Sophosbuvir in neaktivni metabolit(GS-331007) nista zaviralci P-gp in BCRP, zato ni pričakovati povečanja izpostavljenosti zdravil, ki so podlage teh vektorjev.

The AUC0-inf of GS-331007 in patients with ESRD administered with sofosbuvir 1 hour before or 1 hour after haemodialysis was at least 10-fold and 20-fold higher.
Vrednost AUC0-inf GS-331007 pri bolnikih z ESRD pri dajanju sofosbuvirja 1 uro pred hemodializo je bila vsaj 10-krat večja, 1 uro po hemodializi pa vsaj 20-krat večja.

Sofosbuvir and GS-331007 are not inhibitors of P-glycoprotein and BCRP, so the effect of drugs that are substrates for these transporters is not expected to increase.
Sophosbuvir in neaktivni metabolit(GS-331007) nista zaviralci P-gp in BCRP, zato ni pričakovati povečanja izpostavljenosti zdravil, ki so podlage teh vektorjev.

The moderate or high fat meal increased sofosbuvir AUC0-inf by 60% and 78%, respectively, but did not substantially affect the sofosbuvir Cmax.
Obrok z zmerno ali visoko vsebnostjo maščobe je povečal vrednost AUC0-inf za sofosbuvir za 60% in 78%, vendar ni imel večjega vpliva na vrednost Cmax za sofosbuvir.

The sofosbuvir resistance-associated substitution S282T was not detected in the baseline NS5B sequence of any patient in Phase 3 studies by population or deep sequencing.
Substitucije S282T, povezane z odpornostjo na sofosbuvir, niso v izhodiščnem zaporedju NS5B odkrili pri nobenem bolniku v študijah 3. faze s karakterizacijo nukleotidnih sledi genoma ali karakterizacijo strukture genoma.

The antiviral effect of sofosbuvir in vitro against less common genotypes 4, 5 and 6 was similar to that observed in genotypes 1, 2 and 3.
Protivirusna aktivnost cofosbuvira in vitro glede manj pogostih genotipov 4, 5 in 6 je bil podoben genotipom 1, 2 in 3.

Increase in sofosbuvir exposure observed in the pharmacokinetic substudy is not clinically relevant.
Povečanje izpostavljenosti sofosbuvirju, ki so ga opažali v farmakokinetični podštudiji, ni klinično pomembno.

The majority of the sofosbuvir dose recovered in urine was GS-331007(78%) while 3.5% was recovered as sofosbuvir.
Večino odmerka cofosbuvira, izločenega z ledvicami, je predstavljal neaktivni metabolit(GS-331007)(78%), medtem ko je bil 3,5% izločen kot sophosbuvir.

GS-461203(active metabolite sofosbuvir) is not an inhibitor of human DNA and RNA polymerase, nor is it an inhibitor of mitochondrial RNA polymerase.
Aktivni presnovek sophosbuvira(GS-461203) ne zavira polimeraze človeške DNA in RNA ter mitohondrijske RNK polimeraze.

The efficacy of ledipasvir/sofosbuvir in patients who had previously failed treatment with sofosbuvir+ ribavirin± PEG-IFN is supported by two clinical studies.
Učinkovitost ledipasvirja/sofobuvirja pri bolnikih, pri katerih je bilo predhodno zdravljenje s sofobuvirjem+ ribavirinom ± PEG-IFN neuspešno, so podprli z dvema kliničnima študijama.